Abstract

IMPORTANCE Few multicenter pediatric studies have comprehensively described the epidemiologic characteristics of cisplatin-associated acute kidney injury using standardized definitions.

OBJECTIVE To examine the rate of and risk factors associated with acute kidney injury among children receiving cisplatin infusions.

DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study examined children (aged <18 years) recruited from May 23, 2013, to March 31, 2017, at 12 Canadian pediatric academic health centers who were receiving 1 or more cisplatin infusion. Children whose estimated or measured glomerular filtration rate (GFR) was less than 30 mL/min/1.73 m² or who had received a kidney transplant were excluded. Data analysis was performed from January 3, 2018, to September 20, 2019.

EXPOSURES Cisplatin infusions.

MAIN OUTCOMES AND MEASURES The primary outcome was acute kidney injury during cisplatin infusion, defined using a Kidney Disease: Improving Global Outcomes serum creatinine criteria-based definition (stage 1 or higher). The secondary outcome was acute kidney injury defined by electrolyte criteria from the National Cancer Institute Common Terminology Criteria for Adverse Events (grade 1 or higher). Assessments occurred at early (first or second cycle) and late (last or second to last cycle) cisplatin infusions.

RESULTS A total of 159 children (mean [SD] age at early cisplatin infusion, 7.2 [5.3] years; 80 [50%] male) participated. The most common diagnoses were central nervous system tumors (58 [36%]), neuroblastoma (43 [27%]), and osteosarcoma (33 [21%]). Acute kidney injury (by serum creatinine level increase) occurred in 48 of 159 patients (30%) at early cisplatin infusions and 23 of 143 patients (16%) at late cisplatin infusions. Acute kidney injury (by electrolyte abnormalities) occurred in 106 of 159 patients (67%) at early cisplatin infusion and 100 of 143 patients (70%) at late cisplatin infusions. Neuroblastoma diagnosis and higher precisplatin GFR were independently associated with acute kidney injury (serum creatinine level increase) at early cisplatin infusions (adjusted odds ratio [aOR] for neuroblastoma vs other, 3.25; 95% CI, 1.18-8.95; aOR for GFR, 1.01; 95% CI, 1.00-1.03) and late cisplatin infusions (aOR for neuroblastoma vs other, 6.85; 95% CI, 1.23-38.0; aOR for GFR, 1.01; 95% CI, 1.00-1.03). Higher cisplatin infusion dose was also independently associated with acute kidney injury (serum creatinine level increase) at later cisplatin infusions (aOR, 1.05; 95% CI, 1.01-1.10).

Key Points

Question What are the characteristics and risk factors associated with acute kidney injury among children receiving cisplatin infusions?

Findings In this cohort study of 159 cisplatin-treated children, 16% to 30% developed acute kidney injury during earlier (first or second cycle) and later (second to last or last cycle) cisplatin infusion treatment and 70% developed electrolyte disturbances. Cancer type and preinfusion kidney function were significantly associated with acute kidney injury risk at earlier and later infusions, and cisplatin dose was associated with acute kidney injury risk at later infusions.

Meaning The findings suggest that acute kidney injury is common during cisplatin infusions and that rate and risk factors differ at earlier vs later infusions.
CONCLUSIONS AND RELEVANCE  The findings suggest that acute kidney injury is common among children receiving cisplatin infusions and that rate and risk factors differ at earlier vs later infusions. These results may help with risk stratification with a goal of risk reduction.

Introduction

Nephrotoxic medications are associated with acute kidney injury (AKI) in hospitalized children.1,2 Cisplatin, a chemotherapy commonly used to treat pediatric solid tumors (brain tumors, neuroblastoma, hepatoblastoma, and osteosarcoma), is associated with AKI via inflammation, mitochondrial and microvascular dysfunction, and oxidative stress.3-9 Children treated with cisplatin may have an increased risk of later chronic kidney disease (CKD) or hypertension, possibly because of repeated cisplatin-associated AKI episodes.10

Several knowledge gaps remain about cisplatin-associated AKI epidemiologic characteristics. Cisplatin-associated AKI is characterized by electrolyte wasting and/or polyuria with or without a serum creatinine (Scr) level increase.11-15 Depending on definitions used, the cisplatin-associated AKI rate is 27% to 100%.11-20 Few studies have described cisplatin-associated AKI using the Kidney Disease: Improving Global Outcomes (KDIGO) definition.21 However, this definition (mainly Scr based) may not adequately portray the cisplatin-associated AKI phenotype, which includes electrolyte disturbances (hypomagnesemia, hypokalemia, hypophosphatemia, and/or kidney tubular acidosis). A cisplatin-specific AKI definition that includes electrolyte abnormalities may more accurately reflect cisplatin-associated AKI phenotype associations with outcomes. Evidence on factors associated with AKI among children receiving cisplatin is limited; past studies12,13,17,19,22 were small, were single center, and used nonstandardized AKI definitions. Accurate description of cisplatin-associated AKI is needed for effective AKI risk stratification and design of AKI interventional trials to mitigate risk.

Inherent to the primary aim of the Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity study, we aimed to describe the AKI phenotype (rate, severity, and duration) and risk factors associated with AKI during individual cisplatin infusions (early and later in cancer treatment) in children using standardized Scr-based AKI (Scr-AKI) and electrolyte-based AKI (eAKI) definitions.23 We hypothesized that AKI would be common during cisplatin infusions, that AKI would be more common and have unique risk factors at later vs earlier infusions, and that the phenotype would differ when AKI is defined using electrolytes.

Methods

Study Cohort

The ABLE Nephrotoxicity study was a multicenter, prospective cohort study of children treated with cisplatin who were recruited from May 23, 2013, to March 31, 2017, at 12 Canadian pediatric oncology centers.23 Data analysis was performed from January 3, 2018, to September 20, 2019. Inclusion criteria were age younger than 18 years at cancer diagnosis and planned cisplatin treatment (cisplatin naive or received at most 1 cisplatin cycle). Exclusion criteria included kidney transplant or estimated or measured glomerular filtration rate (GFR) less than 30 mL/min/1.73 m². Sites obtained research ethics board approval. Written informed consent (assent when appropriate) was obtained before enrollment. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.24
Study Procedure
Children are typically hospitalized to receive cisplatin. Most cisplatin protocols comprise 2 to 8 cycles given every 3 to 6 weeks; dosages vary by tumor type (e.g., single high-dose bolus [70-100 mg/m²] vs 2-5 days of low-dose bolus [20-60 mg/m² daily]). The first prospective cisplatin study visit occurred shortly after recruitment at the first or second cisplatin cycle of cancer treatment (early visit [EV]). The late visit (LV) occurred at the last or second to last cycle. At the EV and LV, blood (3 mL) and urine (30 mL) samples were collected on the same day but before cisplatin infusion (day 1), the morning after infusion (day 2), and just before hospital discharge (at most day 5 after infusion). The study protocol is shown in eFigure 1 in the Supplement.

Specimens and Measurements
Sites centrifuged blood samples (1000 g for 10 minutes at 21 °C). Serum and urine samples were frozen (−80 °C) until shipment to the McGill University Health Centre. Specimen collection, freezing, and shipment were monitored using Research Electronic Data Capture (REDCap).27 At the McGill University Health Centre, urine samples were thawed and processed (1000 g for 10 minutes); serum and urine samples were measured for creatinine (isotope dilution mass spectrometry–traceable), potassium, magnesium, and phosphorus levels.

Data Collection
Data collection is summarized in eFigure 1 in the Supplement. Baseline (precisplatin) data were collected retrospectively (demographic characteristics [race/ethnicity, classified by site coordinators; options were investigator defined], cancer details, kidney history [hypertension, CKD, AKI, kidney anomalies, and family history]; medications taken 2 weeks before cisplatin treatment; precisplatin treatment measured GFR; and 24-hour creatinine clearance [CrCl]). Baseline GFR was ascertained using measured GFR if available or CrCl if unavailable; if both were unavailable, GFR was estimated using the CKD in Children (CKiD) equation (using the lowest 3-month precisplatin SCr level).28 Decreased GFR was defined using age-normative GFR thresholds.29 From 3 days before to 10 days after study cisplatin infusions, prospective data collection included the following: routinely measured SCr and electrolyte levels, nephrotoxic medications (acyclovir, aminoglycosides, amphotericin B, ifosfamide, nonsteroidal anti-inflammatory drugs, and acetylsalicylic acid), diuretics, and electrolyte supplements (magnesium, phosphorus, and potassium). Immediate precisplatin treatment estimated GFR was calculated using the CKiD equation.28 Data collected throughout cisplatin treatment included dialysis, intensive care unit (ICU) admissions, infections (positive blood culture results and documentation), and AKI episodes between study visits. Completed standardized case report forms were sent to the Epidemiology Coordinating and Research Centre (Edmonton) for data entry (REDCap) with regular data quality queries.27 Quality assurance measures were taken to avoid missing data.

Outcomes
Two cisplatin-associated AKI definitions were ascertained. First, SCr-based AKI was defined and staged using a KDIGO SCr-based definition (primary outcome of stage 1 or higher AKI) (eTable 1 in the Supplement).21 Because cisplatin-associated AKI is nonoliguric, KDIGO urine output criteria were not used. KDIGO timing criteria (48 hours or 7 days) were not used because these were primarily designed for ICU populations.21 Similar to a previous study,30 a 10-day period was used to ascertain AKI, allowing for variable routine follow-up times of laboratory measurements after cisplatin treatment. For EV, the baseline SCr level was the lowest 3-month precisplatin treatment level; for participants with previous cisplatin exposure, 3-day pre-EV infusion values were also used. For LV, the baseline SCr level was the lowest 3-day pre-LV level. Peak SCr level was the highest SCr level 10 days after infusion. Severe SCr-based AKI was KDIGO stage 2 or higher.

Second, eAKI was defined using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (eTable 1 in the Supplement).31 The novel term eAKI was chosen as a
secondary outcome to reflect that electrolyte losses occur because of kidney tubular injury. Using nadir electrolyte values within 10 days after infusion, eAKI was graded based on serum magnesium, potassium, and phosphorus concentrations (any grade 1 or higher abnormality) (eTable 1 in the Supplement). We explored a secondary eAKI definition in which oral or intravenous electrolyte (potassium, magnesium, or phosphorous) supplementation was also considered. Composite AKI was both SCr-based AKI and eAKI. SCr and electrolyte levels measured for routine care and the 3 study-specific measures were used to ascertain AKI at the EV and LV. We decided a priori to evaluate routine vs study-measured laboratory values and exclude measures with evident bias (addressing potential issues with serum storage effects).

We calculated the number of days with SCr-based AKI and eAKI, which was the number of days fulfilling SCr-based AKI and eAKI criteria, respectively, within the 10 days after cisplatin infusion. SCr-based AKI recovery at last SCr level measurement was defined as the last SCr level available in 10 days after infusion less than 1.5 times the baseline SCr level. At all EV and LV sample points, fractional excretion (FE) of electrolytes was calculated as follows:

\[
\text{FE}[\text{Electrolyte}] = \left( \frac{\text{Urine}[\text{Electrolyte}] \times \text{SCr}}{\text{Urine}[\text{Creatinine}] \times \text{Serum}[\text{Electrolyte}]} \right) \times 100 = \text{FE}[\text{Electrolyte}] \%
\]

(Serum Magnesium × 0.7).

Statistical Analysis

Sample size was predetermined based on a convenience sample to balance feasibility and power. Variables were compared between groups using distribution-appropriate tests (Mann-Whitney test, Wilcoxon signed-rank test, 2-tailed, unpaired t test, χ² test, or Fisher exact test). Spearman correlation between routine and study-measured laboratory values was examined. Percent agreement between AKI definitions was evaluated. Undocumented events and data were considered absent (negative).

Variables associated with AKI were evaluated separately for EV and LV using multivariable logistic regression. Candidate risk factors were categorized as baseline (before cisplatin administration), immediately before or on the day of cisplatin administration, and after cisplatin administration. Purposeful selection and manual backward selection were used to select variables for regression models. Variable associations, correlations, and collinearity were assessed. On the basis of the literature and clinical rationale, we a priori forced age into models. Variables associated with AKI in univariable analyses (P < .10) were initially included in multivariable models. Models were reduced (P < .05, for variable retention) to obtain parsimonious models. Variable deletion was confirmed using the backward likelihood ratio test. In final multivariable models, variables not significantly associated with AKI (P > .05) but considered significant confounders (ie, elimination significantly affected other β coefficients) were retained. Model fit was assessed (Hosmer-Lemeshow goodness of fit and area under the receiver operating characteristic curve [AUC]). Odds ratios (ORs) with 95% CIs were calculated. Separate regression models were used for SCr-based AKI and SCr plus eAKI. A 2-tailed P < .05 was considered statistically significant unless stated otherwise. Analyses were performed using Stata software, version 12.1 (StataCorp).

Results

Study Cohort

Twelve of the 17 Canadian pediatric cancer centers (71%) were represented. Of 209 eligible patients approached, 159 were enrolled (76% consent rate [mean [SD] age at early cisplatin infusion, 7.2 [5.3] years; 80 [50%] male]) (Figure). Late visit data were not evaluable for 16 participants because the EV occurred at the last cisplatin cycle (Figure). Specimens were available for 158 patients (99%) at the EV; specimens from 129 of 143 (90%) were available at the LV (Figure). Sample collection was successful (EV, ≥92%; LV, ≥83%) (eTable 2 in the Supplement), and the rate of missing data was low (eTable 3 in the Supplement). At the EV, 91 of 159 participants (57%) were cisplatin naive. The LV occurred at a median of the third cisplatin cycle (interquartile range [IQR], second to fourth cycles);
this was the last cycle for 119 of 143 participants (83%). Throughout cisplatin therapy, no participant received dialysis; 1 died of tumor progression.

**Laboratory Measures**
Routinely measured SCr level correlated strongly with study-measured SCr level (Spearman ρ >0.86) (eTable 4 in the Supplement). Routine phosphorus and magnesium level measurements correlated modestly with study-specific measures (phosphorus: ρ >0.61; magnesium: ρ >0.55). Routine potassium level measurements correlated variably with study-specific values (ρ, 0.33-0.64). Study-measured electrolyte levels were higher than routine measures, likely because of storage and hemolysis. Because the inclusion of study measures would tend to underestimate eAKI, we used all data available (worst of routine and study-specific measures).

**EV SCr-AKI**
**Baseline and AKI Characteristics**
Of 159 participants, 117 (74%) were white. Central nervous system tumors (36%) and neuroblastoma (27%) were the most common diagnoses. At baseline, 8 participants (5%) had a history of hypertension, and 8 had a decreased GFR (measured or estimated) for age.

The study flow diagram outlines the number of patients identified, recruited, and with available data and specimens at each cisplatin study visit (early visit [EV] and late visit [LV]). The top box (number eligible) refers to patients receiving cisplatin during the study activation period (at 6 sites, total number of patients receiving cisplatin may not be completely accurate). A total of 158 study participants had EV samples collected (blood or urine). A total of 129 study participants had LV blood or urine samples collected.
Forty-eight of the 159 participants (30%; 95% CI, 23%-37%) developed SCr-AKI at the EV; 12 of 159 (8%; 95% CI, 3%-12%) had severe SCr-AKI (stage 2 or higher). The median time with SCr-AKI was 2 days (IQR, 1-4 days).

Cancer type and a positive kidney medical history were associated with SCr-AKI (SCr-AKI: 42% CNS tumors, 38% neuroblastoma and 4% osteosarcoma, and 17% positive kidney medical history; no SCr-AKI: 34% CNS tumors, 23% neuroblastoma and 28% osteosarcoma, and 5% positive kidney medical history; other baseline characteristics were not associated with SCr-AKI) (Table 1). Two weeks before cisplatin treatment, nephrotoxic medication administration was uncommon (nonsteroidal anti-inflammatory drugs or acetylsalicylic acid [11%] and methotrexate [7%] were most common) (eTable 5 in the Supplement).

**EV and Cisplatin Treatment Characteristics**

Age younger than 3 years (eFigure 2 in the Supplement) and higher previsit estimated GFR were associated with SCr-AKI at the EV (SCr-AKI: 54% aged <3 years and median eGFR of 166 mL/min/1.73 m²; no SCr-AKI: 23% aged <3 years and median eGFR of 132 mL/min/1.73 m²) (Table 1). Past SCr-AKI was more common in participants who did vs did not develop SCr-AKI (SCr-AKI: 23% with previous AKI; no SCr-AKI: 7% with previous AKI); ICU admission, infections, concurrent nephrotoxins,

---

**Table 1. Characteristics of Study Population at the EV and LV by SCr-AKI Status**

| Characteristic                        | EV SCr-AKI (n = 48) | No SCr-AKI (n = 111) | LV SCr-AKI (n = 23) | No SCr-AKI (n = 120) |
|---------------------------------------|---------------------|----------------------|---------------------|----------------------|
| **Baseline (before first cisplatin infusion)** |         |                      |                     |                     |
| Male                                  | 23 (48)            | 57 (51)              | 8 (35)              | 61 (51)              |
| White race/ethnicity                  | 39 (81)            | 78 (70)              | 18 (78)             | 89 (74)              |
| Cancer diagnosis                      |                     |                      |                     |                     |
| CNS tumor**                           | 20 (42)**c          | 38 (34)              | 11 (48)**d          | 44 (37)              |
| Neuroblastoma                         | 18 (38)            | 25 (23)              | 8 (35)              | 23 (19)              |
| Osteosarcoma                          | 2 (4)               | 31 (28)              | 0 (0)               | 33 (28)              |
| Germ cell tumor                       | 3 (6)               | 11 (10)              | 0 (0)               | 14 (12)              |
| Hepatoblastoma                        | 4 (8)               | 5 (5)                | 3 (13)              | 6 (5)                |
| Other**                               | 1 (2)               | 1 (1)                | 1 (4)               | 0 (0)                |
| Cancer involves 1 or both kidneys     | 5 (10)              | 6 (5)                | 3 (13)              | 4 (3)                |
| Kidney medical history**              | 8 (17)**c           | 5 (5)                | 1 (4)               | 10 (8)               |
| Any nephrotoxic drug before first cisplatin infusion** | 12 (25) | 15 (14) | NA | NA |
| Vancomycin in 2 wk before cisplatin infusion** | 5 (10) | 3 (3) | NA | NA |
| **Immediately before or on the day of EV or LV infusion** |         |                      |                     |                     |
| Age at EV or LV, median (IQR), y      | 2.7 (2.0-6.8)**d   | 7.5 (3.1-13.4)       | 2.6 (2.2-4.7)**e   | 7.7 (2.6-13.7)       |
| Age <3 y                               | 26 (54)**c          | 26 (23)              | 13 (57)**c          | 32 (27)              |
| Cisplatin naive at the EV             | 31 (65)            | 60 (54)              | NA                  | NA                   |
| Previsit eGFR, median (IQR), mL/min/1.73 m²** | 166 (140-206)**d   | 132 (115-155)        | 169 (156-202)**d   | 133 (114-163)        |
| Preinfusion serum level, mean (SD)**  |                     |                      |                     |                     |
| Phosphorus, mg/dL                     | 4.8 (1.6)           | 4.6 (0.9)            | 4.3 (0.8)**c        | 4.8 (0.9)**c         |
| Magnesium, mEq/L                      | 1.6 (0.3)           | 1.6 (0.2)            | 1.5 (0.2)           | 1.6 (0.2)**c         |
| Last cisplatin cycle of treatment at LV | NA                 | NA                  | 19 (83)             | 100 (83)             |
| Cumulative cisplatin dose before the EV or LV, median (IQR), mg/m²** | 82 (77-127)**h     | 109 (77-120)**h      | 168 (154-204)**i   | 224 (167-353)        |
| EV or LV cisplatin infusion dose, median (IQR), mg/m²** | 65 (50-77)          | 59 (49-74)           | 75 (49-80)**e       | 58 (37-71)           |
| **Before EV or LV**                   |                     |                      |                     |                     |
| Infection                             | 6 (13)              | 14 (13)              | 12 (52)             | 38 (32)              |
| PICU admission                        | 1 (2)               | 1 (1)                | 4 (17)              | 9 (8)                |
| SCr-AKI episode**                     | 11 (23)**c          | 8 (7)                | 15 (65)             | 52 (43)              |
| Between EV and LV visits, median (IQR), d | NA                 | NA                  | 42 (29-64)**k       | 69 (42-118)          |
| Concurrent nephrotoxins at EV or LV** | 3 (6)               | 20 (18)              | 2 (9)               | 20 (17)              |

(continued)
radiotherapy (planned in treatment protocol or given), and total cisplatin cycle dose did not differ by SCR-AKI status (Table 1). Participants with SCR-AKI (vs without) had a longer hospital stay (median of 5 days in patients with SCR-AKI and median of 4 days in those without SCR-AKI; Table 1).

**LV SCR-AKI**

**Baseline and AKI Characteristics**

SCR-AKI at the LV was found in 23 of 143 patients (16%; 95% CI, 10%-22%); 7 of 143 (5%; 95% CI, 1%-8%) had severe SCR-AKI (stage 2 or higher) (Table 2). The median time with SCR-AKI was 1 day (IQR, 1-3 days). Cancer type was significantly associated with SCR-AKI (Table 1).

**LV and Cisplatin Treatment Characteristics**

Age younger than 3 years and higher previsit estimated GFR were associated with SCR-AKI (57% aged <3 years and median GFR of 169 mL/min/1.73 m² in those with SCR-AKI and 27% aged <3 years and median GFR of 133 mL/min/1.73 m² in those without SCR-AKI; Table 1). Prior cumulative cisplatin dose was lower and cisplatin infusion dose was higher in participants with SCR-AKI (median prior dose of 168 mg/m² in those with SCR-AKI and 224 mg/m² in those without; median infusion dose of 75 mg/m² in those with SCR-AKI and 58 mg/m² in those without; Table 1). Time between the EV and LV was shorter in participants with (median of 42 days) vs without SCR-AKI (median of 69 days); ICU admission, infections, concurrent nephrotoxins, radiotherapy, and total cisplatin cycle dose were not associated with SCR-AKI (Table 1). Participants with SCR-AKI (vs without) had a longer hospital stay (median [IQR] of 4 [3-11] days in patients with SCR-AKI and 4 [2-5] days in those without SCR-AKI; Table 1).
SCrPlus eAKI and eAKI

A total of 106 of the 159 participants (67%; 95% CI, 59%-74%) developed eAKI at the EV, and 100 of the 143 participants (70%; 95% CI, 62%-78%) developed eAKI at the LV. The median time with eAKI was 2 days (IQR, 1-3 days) at the EV and 2 days (IQR, 1-4 days) at the LV. Thirty-two of 159 patients (20%; 95% CI, 14%-26%) had SCr plus eAKI at the EV, and 16 of 143 (11%; 95% CI, 6%-16%) had SCr plus eAKI at the LV. eTable 6 and eTable 7 in the Supplement list the participant characteristics by eAKI and SCr plus eAKI status.

Hypophosphatemiamainlycontributed to eAKI (Table 3). When including electrolyte supplementation criteria to define eAKI, the hypophosphatemiam rate remained similar (EV: 57%; 95% CI, 49%-65%; LV: 56%; 95% CI, 48%-64%), the hypomagnesemia rate increased (EV: 78%; 95% CI, 71%-84%; LV: 83%; 95% CI, 77%-89%), and the hypokalemiarate increased (EV: 60%; 95% CI, 53%-68%; LV: 61%; 95% CI, 53%-69%). A total of 144 of 159 patients (91%; 95% CI, 86%-95%) had eAKI or received electrolyte supplements at the EV and 132 of 143 patients (92%; 95% CI, 88%-97%) had eAKI or received electrolyte supplements at the LV.

At the EV and LV, phosphorus concentrations decreased significantly from before infusion to after infusion and remained low or decreased at discharge (eFigure 3 in the Supplement). Serum magnesium and potassium concentrations increased from before infusion to after infusion and remained high or increased at discharge.

| Table 2. Rate of SCr-AKI, eAKI, and SCr Plus eAKI and Staging or Grading at the EV and/or LV Using 3 Definitions |
|-------------|-------------------------------|------------------|--------------------------|
| Variable     | Children, No. (%) [95% CI] | SCr-AKI | eAKI | SCr plus eAKI |
| At EV        | Total 48/159 (30) [23-37]   | 106/159 (67) [59-74] | 32/159 (20) [14-26] |
| Stage or grade | 0 111/159 (70) [63-77] | 53/159 (33) [26-41] | NA |
|              | 1 36/159 (23) [16-29]      | 71/159 (45) [37-52] | NA |
|              | 2 10/159 (6) [2-10]        | 17/159 (11) [6-16] | NA |
|              | 3 2/159 (1) [0-3]          | 16/159 (10) [5-15] | NA |
|              | 4 NA 2/159 (1) [0-3]       | NA |
| At LV        | Total 23/143 (16) [10-22]  | 100/143 (70) [62-78] | 16/143 (11) [6-16] |
| Stage or grade | 0 120/143 (84) [78-90] | 43/143 (30) [22-38] | NA |
|              | 1 16/143 (11) [6-16]       | 76/143 (53) [45-61] | NA |
|              | 2 5/143 (3) [4-7]          | 12/143 (8) [4-13]  | NA |
|              | 3 2/143 (1) [0-3]          | 10/143 (7) [3-11]  | NA |
|              | 4 NA 2/143 (1) [0-3]       | NA |
| At EV or LV  | Total 59/159 (37) [30-45]  | 134/159 (84) [79-90] | 41/159 (26) [19-33] |
| Stage or grade | 0 100/159 (63) [55-70] | 25/159 (16) [10-21] | NA |
|              | 1 42/159 (26) [19-33]      | 81/159 (51) [43-59] | NA |
|              | 2 13/159 (8) [4-12]        | 25/159 (16) [10-21] | NA |
|              | 3 4/159 (3) [0-5]          | 24/159 (15) [9-21]  | NA |
|              | 4 NA 4/159 (3) [0-5]       | NA |
| At EV and LV | Total 12/143 (8) [3-12]    | 72/143 (50) [42-59] | 7/143 (5) [1-8] |
| Stage or grade | 0 131/143 (92) [87-96] | 71/143 (50) [41-58] | NA |
|              | 1 5/143 (3) [0-7]          | 36/143 (25) [18-32] | NA |
|              | 2 6/143 (4) [1-8]          | 17/143 (12) [7-17]  | NA |
|              | 3 1/143 (1) [0-2]          | 16/143 (11) [6-16]  | NA |
|              | 4 NA 3/143 (2) [0-4]       | NA |

Abbreviations: AKI, acute kidney injury; eAKI, electrolyte-based AKI; EV, early visit; LV, late visit; NA, not applicable; SCr-AKI, serum creatinine-based AKI.
remained higher than before infusion at discharge (eFigure 3 in the Supplement). Fractional extraction of all electrolytes increased significantly from before infusion to after infusion (eTable 8 in the Supplement).

**Characteristics by Cancer Type**

Participants with neuroblastoma and hepatoblastoma were younger and had high SCr-AKI rates (eTable 9 in the Supplement). Those with osteosarcoma and germ cell tumors had low SCr-AKI rates; none developed SCr-AKI at the LV (eTable 9 in the Supplement). Cisplatin dosage and administration schedule varied by cancer type (eTable 10 in the Supplement). Treatment protocols of participants with germ cell tumors, osteosarcoma, and hepatoblastoma included fewer potential nephrotoxins (eTable 10 in the Supplement). Treatment protocols of 2 of the 159 participants (1%) included amifostine, and treatment protocols of 13 of the 159 participants (8%) included mesna.

**AKI Definition and Visit Comparisons**

Discordance between SCr-AKI and eAKI classifications was 57% at the EV and 64% at the LV. Of 48 participants with SCr-AKI at the EV, 12 of 41 (29%; 95% CI, 15%-44%) also had SCr-AKI at the LV; of 111 without SCr-AKI at the EV, 11 of 102 (11%; 95% CI: 5%-17%) had SCr-AKI at the LV. The median cisplatin infusion dose was lower at the LV (58 mg/m²; IQR, 37-74 mg/m²; \( P < .05 \)).

**Table 3. Description of AKI Features at the EV and LV**

| Feature                          | Children, No. (%) [95% CI] |
|----------------------------------|-----------------------------|
| **SCr-AKI**                      |                             |
| Increase in SCr, median (IQR), % | 74 (60-103) (n = 48)        |
| Time to peak SCr of SCr-AKI, d   | 2 (1-5) (n = 48)            |
| Time to SCr-AKI diagnosis, median (IQR), d | 2 (1-5) (n = 48) |
| SCr-AKI recovery at last SCr measurement, No./total No. (%)a | 22/48 (46) |
| Completeb                       | 10/48 (21) |
| Partialc                        | 12/48 (25) |
| None                           | 26/48 (54) |
| **eAKI**                         |                             |
| Time to nadir electrolyte of eAKI, median (IQR), d | 2 (1-4) (n = 106) |
| Time to eAKI diagnosis, median (IQR), d | 1.5 (1-3) (n = 106) |
| Hypophosphatemia                | 88/158 (56) [48-64]         |
| Grade 0                         | 70 (44) [36-52]             |
| Grade 1                         | 62 (39) [32-47]             |
| Grade 3                         | 21 (13) [8-19]              |
| Grade 4                         | 5 (3) [4-6]                 |
| Hypomagnesemia                  | 42/158 (27) [20-34]         |
| Grade 0                         | 116 (73) [66-80]            |
| Grade 1                         | 39 (25) [18-31]             |
| Grade 3                         | 2 (1) [0-3]                 |
| Grade 4                         | 0 (0) [0-0]                 |
| Hypokalemia                     | 40/159 (25) [18-32]         |
| Grade 0                         | 119 (75) [68-82]            |
| Grade 1                         | 27 (17) [11-23]             |
| Grade 3                         | NA                         |
| Grade 4                         | 11 (7) [3-11]               |
| **Abbreviations:** AKI, acute kidney injury; eAKI, electrolyte-based AKI; EV, early visit; IQR, interquartile range; LV, late visit; NA, not applicable; SCr, serum creatinine; SCr-AKI, serum creatinine-based AKI.  

a Last SCr measurement available in the 10 days after cisplatin infusion less than 1.5 times baseline.  
b Last SCr measurement available in the 10 days after cisplatin infusion less than 1.2 times baseline.  
c Last SCr measurement available in the 10 days after cisplatin infusion less than 1.2 times baseline.  
d Last SCr measurement available in the 10 days after cisplatin infusion 1.5 times or greater than baseline.  
e Hypophosphatemia and hypomagnesemia status could not be assessed in 1 participant at the EV because no routine phosphorous or magnesium values were available and the study blood specimens were not successfully collected.
Factors Associated With AKI Risk

In multivariable analyses, central nervous system tumors, neuroblastoma, and higher pre-EV estimated GFR were associated with SCr-AKI at the EV (model AUC, 0.78; 95% CI, 0.69-0.86) (Table 4). For SCr plus eAKI at the EV, higher pre-EV estimated GFR and kidney medical history were associated with AKI (model AUC, 0.77; 95% CI, 0.68-0.86) (Table 4). Age younger than 3 years, neuroblastoma, higher LV cisplatin infusion dose, and higher pre-LV estimated GFR were associated with SCr-AKI at the LV (model AUC, 0.82; 95% CI, 0.74-0.91) (Table 4). Meaningful multivariable analyses for SCr plus eAKI at the LV were not feasible because of low event rate.

Table 4. Unadjusted and Adjusted Risk Factors for AKI at the EV and LV

| Variable | Unadjusted OR (95% CI) | P Value | Adjusted OR (95% CI) | P Value |
|----------|------------------------|---------|----------------------|---------|
| Predicting SCr-AKI at the EV (n = 159) | | | | |
| Age <3 y at the EV<sup>a</sup> | 3.86 (1.88-7.92) | <.001 | 1.76 (0.74-4.19) | .20 |
| Other cancers<sup>b,c</sup> | 1 [Reference] | NA | 1 [Reference] | NA |
| CNS tumors | 2.53 (1.06-6.03) | .04 | 3.29 (1.18-9.18) | .02 |
| Neuroblastoma | 3.46 (1.39-8.60) | .01 | 3.25 (1.18-8.95) | .02 |
| Pre-EV eGFR | 1.02 (1.01-1.03) | <.001 | 1.01 (1.005-1.03) | .004 |
| Concurrent nephrotoxins<sup>d</sup> | 3.03 (0.086-1.07) | .07 | 0.38 (0.09-1.52) | .17 |
| Predicting SCr plus eAKI at the EV (n = 159) | | | | |
| Age <3 y at the EV<sup>a</sup> | 2.98 (1.34-6.60) | .007 | 1.42 (0.53-3.84) | .49 |
| Pre-EV eGFR | 1.02 (1.01-1.03) | .001 | 1.01 (1.003-1.02) | .01 |
| Kidney medical history<sup>e</sup> | 5.65 (1.75-18.2) | .004 | 4.97 (1.37-18.0) | .02 |
| Vancomycin in 2 weeks before the first cisplatin infusion<sup>f</sup> | 4.39 (1.04-18.6) | .05 | 3.10 (0.58-16.7) | .19 |
| Predicting SCr-AKI at the LV (n = 143) | | | | |
| Age <3 y at the LV<sup>a</sup> | 3.58 (1.43-8.96) | .007 | 1.73 (0.61-4.88) | .30 |
| Other cancers<sup>c</sup> | 1 [Reference] | NA | 1 [Reference] | NA |
| CNS tumors | 3.31 (0.99-11.1) | .05 | 1.65 (0.41-6.60) | .48 |
| Neuroblastoma | 4.61 (1.26-16.8) | .02 | 6.85 (1.23-38) | .03 |
| LV cisplatin infusion dose, mg/m<sup>2</sup> | 1.03 (1.01-1.06) | .01 | 1.05 (1.01-1.10) | .03 |
| Pre-LV eGFR | 1.02 (1.01-1.03) | <.001 | 1.01 (1.002-1.03) | .02 |

Abbreviations: AKI, acute kidney injury; CNS, central nervous system; eAKI, electrolyte-based AKI; eGFR, estimated glomerular filtration rate; EV, early visit; LV, late visit; NA, not applicable; OR, odds ratio; SCr, serum creatinine; SCr-AKI, serum creatinine–based AKI.

<sup>a</sup> Age was categorized as younger than 3 years because there was a clear increased AKI risk in this group (eFigure 2 in the Supplement) and to increase clinical usefulness. Age younger than 3 years was forced into all models.

<sup>b</sup> Other cancer diagnoses include osteosarcoma, germ cell tumors, hepatoblastoma, lymphoma, and nasopharyngeal carcinoma.

<sup>c</sup> On the basis of distribution, cancer type was expressed as 3 categories: CNS tumors, neuroblastoma, and other cancers (osteosarcoma, germ cell tumors, hepatoblastoma, and others).

<sup>d</sup> Concurrent nephrotoxins was kept in the SCr-AKI EV model because it was an important confounder (caused a ≈20% change in the point estimate of other covariates).

<sup>e</sup> Kidney medical history included hypertension, treatment with antihypertensives, family history of kidney disease, chronic kidney disease, dialysis, congenital kidney anomaly, kidney stones, vesicoureteral reflux, urinary tract infection, or AKI.

<sup>f</sup> Vancomycin in the 2 weeks before the first cisplatin infusion was kept in the SCr plus eAKI EV model because it was an important confounder (caused a ≈20% change in the point estimate of other covariates).

<sup>g</sup> Cancer types were 53 CNS tumors, 9 neuroblastoma, and 57 other cancers. Other cancer diagnoses include osteosarcoma (n = 33), germ cell tumors (n = 14), hepatoblastoma (n = 9), and others (n = 1 with nasopharyngeal carcinoma).
Discussion

To our knowledge, this is the first multicenter, prospective, pediatric study using a KDIGO-based AKI definition to study cisplatin-associated AKI characteristics and risk factors. SCr-AKI was more common at the EV compared with the LV. Concordance between SCr-AKI and eAKI was poor; eAKI was more common than SCr-AKI.

The AKI definition affected the AKI rate. The SCr-AKI rate at the EV was comparable to previous studies (27%-75%), and the LV SCr-AKI rate was comparable to adult estimates. However, most studies evaluated SCr-AKI throughout chemotherapy (including multiple chemotherapies and cycles), whereas we evaluated 2 individual cisplatin cycles, which may be more relevant for individual patient care. Discordance between SCr-AKI and eAKI suggests that each provides distinct information; eAKI may more directly reflect tubular injury. SCr may be an inaccurate AKI marker in this setting because of low muscle mass. Other biomarkers (eg, cystatin C) should be evaluated. Fluids are commonly administered before cisplatin infusion, concurrently, and after infusion, which could dilute SCR values, but we did not capture fluid details. The eAKI rate may be inflated if electrolyte supplementation is included in the eAKI definition. There was cross-site practice variation in prophylactic electrolyte (magnesium and potassium) supplementation. Therefore, the eAKI definition may need to be modified for electrolytes not routinely prophylactically supplemented. Future research should determine how different cisplatin-associated AKI definitions affect associations with long-term outcomes.

Similar to other populations, young age was associated with SCr-AKI. Interindividual variability in cisplatin pharmacokinetics and pharmacodynamics and standard practice determine dose of cisplatin based on body size in young children may partly explain this finding. Higher baseline estimated GFR was independently associated with AKI. This somewhat paradoxical finding has been consistently described in pediatric AKI studies, without any satisfying explanations. One theory is that children with higher baseline estimated GFR may have lower muscle mass and poor nutrition, although this has never been reported. Another theory is that excessive hydration may dilute SCr; however, this has not been proven, and we did not collect hydration protocol information or mannitol use. In addition, we were unable to assess whether some patients had syndrome of inappropriate antidiuretic hormone secretion, contributing to SCr dilution. Further research should determine the effect of hydration protocols on SCr and cisplatin-associated AKI.

Cisplatin dosage and medications may be associated with AKI. In adults, single-bolus cisplatin infusions are more nephrotoxic than infusions administered for 2 to 5 days. In our study, participants with neuroblastoma received the highest total cisplatin cycle dose, and their protocols contained the highest number of nephrotoxins. These factors could contribute to high AKI risk for neuroblastoma and central nervous system tumors. Synergistic nephrotoxic effects with other drugs remain unclear. Genetic differences in cisplatin metabolizing enzymes or alterations in cisplatin metabolism from other medications are possible. In addition, the lower cisplatin infusion dose at the LV may explain the low SCr-AKI rate at LV. We were unable to assess whether there were changes in cisplatin dose, treatment protocol, or fluid administration because of nephrotoxic effects. Furthermore, despite receiving the highest pre-LV cumulative cisplatin dose, no participants with osteosarcoma developed SCr-AKI, likely explaining associations between low prior cumulative cisplatin dose and SCr-AKI at LV. High cumulative dose is typically associated with nephrotoxic effects near cancer treatment end and may be more important in long-term or chronic nephrotoxicity. However, the LV infusion dose was higher in participants with SCr-AKI, suggesting that during later individual cisplatin cycles, planned higher dose may be associated with AKI during that cycle. After receiving multiple cisplatin doses, patients may experience unresolved tubular injury, increasing susceptibility of further injury. Although further research is needed with larger sample sizes to differentiate the contributions of risk factors and their associations, identified risk factors should be confirmed for identifying future individual cisplatin-associated AKI risk with a goal of early management. It remains unclear how cisplatin dose should be adjusted because of AKI.
In this pediatric, multicenter study, cisplatin-associated SCr-AKI and eAKI were common and transient; however, long-term clinical and subclinical effects remain unknown. SCr-AKI occurred early during cisplatin treatment, suggesting that AKI monitoring is needed at cisplatin treatment commencement. The identified variables associated with AKI in children receiving cisplatin need validation but represent a potentially applicable AKI risk profile to help clinical decision-making and management (eg, dose, use of other nephrotoxins, and observation duration). Clinical risk profiling may enhance conduct of future cisplatin-associated AKI intervention trials, including antioxidants, kidney blood flow modifiers, and anti-inflammatory mediators.46-50

Strengths and Limitations
This study has strengths, including the prospective, multicenter design, the heterogeneous group of children treated for cancer (enhancing generalizability), and the use of definitions based on standardized AKI definitions with detailed SCr and electrolyte profiles with comprehensive AKI evaluation. This study also has limitations. The modest sample size precluded subgroup analyses (eg, cancer types), limited multivariable analyses, and limited the assessment of confounding and interactions. The study population was predominantly white, limiting race/ethnicity association evaluations. We did not collect detailed information on or evaluate cancer staging and severity or previous cancers and treatments.

Conclusions
The findings suggest that AKI is common among children receiving cisplatin infusions and that rate and risk factors differ at earlier vs later infusions. These results may help with risk stratification with a goal of risk reduction.

ARTICLE INFORMATION
Accepted for Publication: February 22, 2020.
Published: May 8, 2020. doi:10.1001/jamanetworkopen.2020.3639
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 McMahon KR et al. JAMA Network Open.
Corresponding Author: Michael Zappitelli, MD, MSc, Toronto Hospital for Sick Children, Department of Pediatrics, Division of Nephrology, University of Toronto, 686 Bay St, 11th Floor, Room 11.9722, Toronto, ON M5G 0A4, Canada (michael.zappitelli@sickkids.ca).
Author Affiliations: Research Institute of the McGill University Health Centre, Montreal Children's Hospital, Division of Nephrology, Department of Pediatrics, McGill University Health Centre, Montreal, Quebec, Canada (McMahon, Palijan, Yordanova, Crépeau-Hubert); Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada (McMahon); British Columbia Children's Hospital, Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada (Rasshel, Schultz); British Columbia Children's Hospital, Division of Pediatric Nephrology, Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada (Blydt-Hansen, Mammen); CancerCare Manitoba, Division of Pediatric Oncology-Hematology-BMT, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada (Cuvelier); Section of Pediatric Nephrology, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada (Pinsk); BC Children's Hospital Research Institute, Department of Pediatrics, Division of Translational Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada (Carleton); Epidemiology Coordinating and Research Centre, Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada (Tsuyuki, Boyko); Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada (Ross); Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada (Huynh); Peter Gilgan Centre For Research and Learning, Toronto, Ontario, Canada (Wang, Zappitelli); Department of Pediatrics, Division of Pediatric Nephrology, McGill University Health Centre, Montreal, Quebec, Canada (Zappitelli); Now with Toronto Hospital for Sick Children, Department of Pediatrics, Division of Nephrology, University of Toronto, Toronto, Ontario, Canada (Zappitelli).
Author Contributions: Dr Zappitelli had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: McMahon, Rassekh, Schultz, Blydt-Hansen, Cuvelier, Pinsk, Ross, Palijan, Zappitelli.

Acquisition, analysis, or interpretation of data: McMahon, Rassekh, Blydt-Hansen, Cuvelier, Mammen, Pinsk, Carleton, Tsuyuki, Ross, Huynh, Yordanova, Crépeau-Hubert, Wang, Boyko, Zappitelli.

Drafting of the manuscript: McMahon, Mammen, Ross, Zappitelli.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: McMahon, Mammen, Wang, Zappitelli.

Obtained funding: McMahon, Rassekh, Schultz, Blydt-Hansen, Cuvelier, Tsuyuki, Ross, Palijan, Huynh, Yordanova, Boyko, Zappitelli.

Supervision: McMahon, Rassekh, Schultz, Cuvelier, Palijan, Zappitelli.

Conflict of Interest Disclosures: Ms McMahon reported receiving a Doctoral Training Scholarship from Fonds de recherche du Québec-Santé during the conduct of the study. Drs Rassekh, Blydt-Hansen, Cuvelier, Tsuyuki, and Dr Zappitelli reported receiving grants from the Canadian Institutes of Health Research during the conduct of the study. Dr Tsuyuki reported receiving grants from Sanofi Canada outside the submitted work. Dr Zappitelli reported receiving compensation as chair of the Safety Review Committee for a drug to treat cystinosis from Eloxx Pharmaceuticals outside the submitted work. This disease and Dr Zappitelli's role has no relation with the work submitted. No other disclosures were reported.

Funding/Support: This work was supported by a Team Grant from the Canadian Institutes of Health Research and its partners, the Canadian Cancer Society, the CI7 Research Network, the Garron Family Cancer Center at the Hospital for Sick Children, and the Pediatric Oncology Group of Ontario (Dr Schultz, Baruchel, McBride, Mitchell, Rassekh, Tsuyuki, and Zappitelli) and a Fonds de recherche du Québec-Santé Doctoral Training Bursary (Ms McMahon). Dr Ross is supported by a Michael Smith Foundation for Health Research Scholar Award.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: Applying Biomarkers to Minimize Long-term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group: Study Investigators and Collaborators: Sylvain Baruchel, MD; Eric Bouffet, MD; Tom Blydt-Hansen, MD; Bruce C. Carleton, PharmD; Geoff D. E. Cuvelier, MD; Sunil Desai, MBChB; Prasad Devarajan, MD; Conrad Fernandez, MD; Adam Fleming, MD; Paul Gibson, MD; Caroline Lavenderière, MD; Victor Lewis, MD; Cherry Mammen, MD, MHSc; Mary L. McBride, MSc; Bruno Michon, MD; Lesley G. Mitchell, MSc; Maury Pinsk, MD; Raveena Rampal, MBChB; Shahrad Rod Rassekh MD, MHSc; Colin J. Ross, PhD; Christine Sabapathy, MD; Kirk R. Schultz, MD; Ross T. Tsuyuki PharmD MSc; Michael Zappitelli, MD, MSc; Alexandra Zorzi, MD.

Additional Contributions: We acknowledge the work of the following clinical research personnel for their involvement in the study: Pina Giuliano, Karen Mazil, Jessica Scheidl, Susan Talmey and Tao Wang (Alberta Children's Hospital, Calgary, Alberta, Canada); Octavia Choi, Cecilia Crosby, Jessica Davis, Fatima Dharsee, Mateo Farfan, Rohan Kakkar, Nicole Kelly, Alecia Lim, Alison Oger, Ritu Ratan, Jennifer Sergeant and Grace Tam (British Columbia Children's Hospital, Vancouver, British Columbia, Canada); Nancy Coreas, Megan Friesen, Rebekah Hiebert, Jodi Karwacki, Krista Mueller, Ashley Ouellette and Kiera Unger (CancerCare Manitoba, Winnipeg, Manitoba, Canada); Barbara Desbiens, Melanie Ernst, Marie-Christine Gagnon and Nadine Roy (Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, Quebec, Canada); Ernestine Chablis, Angélique Courtade, Catherine Desjean, Marie Saint-Jacques, Martine Therrien and Caroline Tra (Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada); Sandra Blamires, Tianna Deluzio, Becky Malkin, Mariam Mikhail and Leslie Paddock (Children's Hospital: London Health Sciences Centre, London, Ontario, Canada); Nathan Adolphe, Brooke Bowerman, Isabelle Laforest, Oluwatosin Adeniyi, Kelly-Ann Ramakko and Jenna-Lee Tremblay (Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada); Mandy Bouchard (IWK Health Centre, Halifax, Nova Scotia, Canada); Shawde Harris and Rachel Simpson (McMaster Children's Hospital, Hamilton, Ontario, Canada); Anelise Espiritu Santo, Jackie Girgis, Dominique Laleniare, Martine Nagy and Sandra Pepin (Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada); Linda Churcher, Dianne Cortez, Kevin Dietrich, Brenda Ennis, Nicholas Howe, Crystal Lefebvre, Nicole Oreill and Holly Sykora (Stollery Children's Hospital, Edmonton, Alberta, Canada); Rachel Alix, Beren Avci, Aparna Bhan, Eric Lee, Darshika Mistry, Niwethaa Nadesan, Subitha Rajakumar, Megan Wood and Elzye Yamasaki (The Hospital for Sick Children, Toronto, Ontario, Canada). Thank you to the EPICORE Centre team (Departments of Pharmacology and Medicine, University of Alberta, Edmonton, Canada) for data support, entry, queries and management. We would like to thank Anat Halevy, MSc (University of British Columbia, Vancouver, Canada), for the ABLE Study support. Thank you to Michael Pizzi and Olivier
We acknowledge the contributions of Pouliot (Research Institute of the McGill University Health Centre team members) for their contributions. We also thank Jasmine Lee, MSc (Hospital for Sick Children, Toronto, Ontario, Canada), for her contributions to the study. These individuals were compensated for their work. We also give our sincerest and deepest gratitude to all the study participants and their families.

REFERENCES

1. Moffett BS, Goldstein SL. Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children. *Clin J Am Soc Nephrol*. 2011;6(4):856-863. doi: 10.2215/CJN.08110910

2. Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. *Am J Kidney Dis*. 2005;45(1):96-101. doi: 10.1053/j.ajkd.2004.09.028

3. Xu Y, Ma H, Shao J, et al. A role for tubular necroptosis in cisplatin-induced AKI. *J Am Soc Nephrol*. 2015;26(1):2647-2658. doi: 10.1681/ASN.2014080741

4. Dasari S, Tchounwou PB. Cisplatin in cancer therapy- molecular mechanisms of action. *Eur J Pharmacol*. 2014;740:364-378. doi: 10.1016/j.ejphar.2014.07.025

5. Luke DR, Vadiei K, Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. *Nephrol Dial Transplant*. 1992;7(1):1-7.

6. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. *J Clin Invest*. 2002;110(6):835-842. doi: 10.1172/JCI200215606

7. Karasawa T, Stegger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. *Toxical Lett*. 2015;237(3):219-227. doi: 10.1016/j.toxlet.2015.06.012

8. Fujieda M, Matsunaga A, Hayashi A, Tauchi H, Chayama K, et al. A role for tubular necroptosis in cisplatin-induced AKI. *J Am Soc Nephrol*. 2015;26(11):2647-2658. doi: 10.1681/ASN.2014080741

9. Luke DR, Vadiei K, Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. *Nephrol Dial Transplant*. 1992;7(1):1-7.

10. Goren MP, Wright RK, Horowitz ME. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. *Cancer Chemother Pharmacol*. 1986;18(1):69-73. doi: 10.1007/BF00253068

11. Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. *Med Pediatr Oncol*. 1997;28(1):35-40. doi: 10.1002/(SICI)1096-911X(199701)28:1<35::AID-MPO7>3.0.CO;2-U

12. Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. *Eur J Cancer*. 2009;45(18):3213-3219. doi: 10.1016/j.ejca.2009.06.032

13. Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. *Eur J Cancer*. 2009;45(18):3213-3219. doi: 10.1016/j.ejca.2009.06.032

14. McMahon KR, Harel-Sterling M, Pizzi M, Huynh L, Zappitelli M. Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study. *Pediatr Nephrol*. 2018;33(12):2311-2320. doi: 10.1007/s00467-018-3976-5

15. Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW. The influence of age on nephrotoxicity following chemotherapy in children. *Br J Cancer Suppl*. 1992;18:S30-S35.

16. Sterling M, Al-Imami Z, McMahon KR, et al. Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy. *Pediatr Blood Cancer*. 2017;64(10). doi: 10.1002/pbc.26538

17. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl*. 2012;2(1):1-138.
22. Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M. Pharmacokinetics of cisplatin and relation to nephrotoxicity in pediatric patients. Eur J Clin Pharmacol. 2001;57(5):393-402. doi:10.1007/s002280100319

23. McMahon KR, Rod Rasselh S, Schultz KR, et al; Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group. Design and methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: a prospective observational cohort study. Can J Kidney Health Dis. 2017;4:2054358117690338. doi:10.1177/2054358117690338

24. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X

25. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol. 1994;12(12):2607-2613. doi:10.1200/JCO.1994.12.12.2607

26. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202-4208. doi:10.1200/JCO.2006.06.4980

27. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629-637. doi:10.1681/ASN.2008030287

28. Hessey E, Ali R, Dorais M, et al. Renal function follow-up and renal recovery after acute kidney injury in critically ill children. Pediatr Crit Care Med. 2017;18(8):733-740. doi:10.1097/PCC.0000000000001166

29. Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol. 2018;36(7):682-688. doi:10.1200/JCO.2017.75.7161

30. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. National Institutes of Health, National Cancer Institute; 2010;1-194. Accessed September 8, 2017. https://evs.nci.nih.gov/ftp1/CTCAE/About.html

31. Topf JM, Murray PT. Hypomagnesemia and hypermagnesemia. Rev Endocr Metab Disord. 2003;4(2):195-206. doi:10.1023/A:1022995032187

32. Lavole A, Danel S, Baudrin L, et al. Routine administration of a single dose of cisplatin ≥ 75 mg/m² after short hydration in an outpatient lung-cancer clinic. Bull Cancer. 2012;99(4):E43-E48. doi:10.1684/bdc.2012.1555

33. Bhat YZ, Cudapahornchul P, Ginsburg K, et al. Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study. PLoS One. 2015;10(11):e0142225. doi:10.1371/journal.pone.0142225

34. Ishitsuka R, Miyazaki J, Ichioha D, et al. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients. Clin Exp Nephrol. 2017;21(4):732-740. doi:10.1007/s10157-016-1327-z

35. Stewart DJ, Dulberg CS, Mikhail NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40(4):293-308. doi:10.1007/s002800050661

36. Rades D, Seidl D, Jansson S, et al. Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): is 20mg/m² cisplatin on five days every four weeks an alternative to 100mg/m² cisplatin every three weeks? Oral Oncol. 2016;59:67-72. doi:10.1016/j.oraloncology.2016.06.004
42. Shord SS, Thompson DM, Krempl GA, Hanigan MH. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs. 2006;17(2):207-215. doi:10.1097/00001813-200602000-00013

43. Jiménez-Triana CA, Castelán-Martínez OD, Rivas-Ruiz R, et al; Canadian Pharmacogenomics Network for Drug Safety Consortium. Cisplatin nephrotoxicity and longitudinal growth in children with solid tumors: a retrospective cohort study. Medicine (Baltimore). 2015;94(34):e1413. doi:10.1097/MD.00000000000001413

44. Landau SI, Guo X, Velazquez H, et al. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease. Kidney Int. 2019;95(4):797-814. doi:10.1016/j.kint.2018.11.042

45. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994-1007. doi:10.1038/sj.ki.5002786

46. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14(7):2101-2112. doi:10.1200/JCO.1996.14.7.2101

47. Benoehr P, Krueht P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J Am Soc Nephrol. 2005;16(2):452-458. doi:10.1681/ASN.2004030225

48. Ghorbani A, Omidar B, Parsi A. Protective effect of selenium on cisplatin induced nephrotoxicity: a double-blind controlled randomized clinical trial. J Nephropathol. 2013;2(2):129-134. doi:10.5812/nephropathol.10656

49. Bajwa A, Rosin DL, Chriscicki P, et al. Sphingosine 1-phosphate receptor-1 enhances mitochondrial function and reduces cisplatin-induced tubule injury. J Am Soc Nephrol. 2015;26(4):908-925. doi:10.1681/ASN.2013121351

50. Park JH, Jang HR, Kim DH, et al. Early, but not late, treatment with human umbilical cord blood-derived mesenchymal stem cells attenuates cisplatin nephrotoxicity through immunomodulation. Am J Physiol Renal Physiol. 2017;313(4):F984-F996. doi:10.1152/ajprenal.00097.2016

SUPPLEMENT.
eFigure 1. Diagram of the Study Protocol
eFigure 2. Relationship Between Age Tertiles and SCR-AKI at EV
eFigure 3. Serum Phosphorous, Magnesium and Potassium Levels Measured at EV and LV Cisplatin Cycles
eTable 1. Serum Creatinine (SCR)-Acute Kidney Injury (AKI) Staging Outlined by the Kidney Disease: Improving Global Outcomes (KDIGO) Guidelines and Electrolyte-AKI (eAKI) Grading Based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4
eTable 2. Blood and Urine Collection Success and Analyte Measurements Obtained at the Earlier Cisplatin Visits (EV) and Later Cisplatin Visits (LV)
eTable 3. Description of Data Collection Success Rate and Missing Data Rate
eTable 4. Correlation Between Serum Laboratory Values Measured By Routine Care and Study-Specific Values
eTable 5. Medications given at Baseline, Prior to, 1 Week Before, 3 Days Before and After Cisplatin Infusion at Earlier Cisplatin Visits (EV) and Later Cisplatin Visits (LV)
eTable 6. Characteristics of Study Population at Earlier Cisplatin Infusion Visit (EV) and Later Cisplatin Infusion Visit (LV), Comparing Patients With Versus Without Electrolyte-Defined AKI (eAKI) With Cisplatin Infusion
Table 7. Characteristics of Study Population at Earlier Cisplatin Infusion Visit (EV) and Later Cisplatin Infusion Visit (LV), Comparing Patients With Versus Without AKI Defined by Having Both Serum Creatinine and Electrolyte-Defined AKI (SCR + eAKI) With Cisplatin Infusion
Table 8. Fractional Excretion of Electrolytes at Earlier Cisplatin Infusion Visit (EV) and Later Cisplatin Infusion Visit (LV)
eTable 9. Characteristics of Study Participants at EV and LV Stratified by Cancer Type
eTable 10. Cancer Treatment Details at Earlier Cisplatin Infusion Visit (EV) and Later Cisplatin Infusion Visit (LV) Stratified by Cancer Type